Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts

Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) increasingly being viewed as pote...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:SAMJ: South African Medical Journal 2020-02, Vol.110 (2), p.154-158
Hauptverfasser: Norris, S.A., Huddle, K.R., Klipstein-Grobusch, K., Soepnel, L., Levitt, N., Nicolaou, V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 158
container_issue 2
container_start_page 154
container_title SAMJ: South African Medical Journal
container_volume 110
creator Norris, S.A.
Huddle, K.R.
Klipstein-Grobusch, K.
Soepnel, L.
Levitt, N.
Nicolaou, V.
description Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) increasingly being viewed as potential alternatives.Objectives. To compare maternal and neonatal outcomes in two cohorts of women with GDM exposed to either insulin monotherapy or OHAs.Methods. A retrospective medical record review at Chris Hani Baragwanath Academic Hospital in South Africa was conducted for women with GDM diagnosed using the 100 g oral glucose tolerance test and/or random capillary blood glucose >11.1 mmol/L in 2010 - 2014. The findings were compared with a previous audit at the same clinic for the period 1992 - 2002. Variables of interest included maternal demographics, maternal comorbidities, glycaemic indices, treatments used during pregnancy, and obstetric and neonatal outcomes.Results. A total of 192 women with GDM were identified for 2010 - 2014, and there were 348 women in the previous audit (1992 - 2002). Baseline characteristics and outcomes of women in the two cohorts were similar apart from earlier presentation (mean (standard deviation) gestational age (GA) 27 (7.5) weeks v. 28.3 (6.4) weeks; p=0.04), lower GA at delivery (36.3 (3.6) weeks v. 37 (1.6) weeks); p=0.008) and lower macrosomia rates (12.5% v. 4.9%; p=0.011) in the later cohort. When comparing the individual OHAs against insulin in the later cohort, both agents were comparable to insulin in terms of maternal and neonatal outcomes.Conclusions. This study contributes to the paucity of data on the safety of OHAs in GDM pregnancy in terms of maternal and neonatal outcomes. OHAs were shown to be an effective alternative to insulin for women with GDM in whom lifestyle measures fail, particularly in a resource-poor setting.
doi_str_mv 10.7196/SAMJ.2020.v110i2.14024
format Article
fullrecord <record><control><sourceid>gale_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0256_95742020000200019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A613203484</galeid><sabinet_id>https://hdl.handle.net/10520/EJC-1bc9dd8c1d</sabinet_id><scielo_id>S0256_95742020000200019</scielo_id><sourcerecordid>A613203484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-9e67ea5631d35a89c642ea2847b4320d18ee687c3d4b5e41be79669393f201823</originalsourceid><addsrcrecordid>eNpVkl2L1DAUhosoOK7-BQkI4s2MSdr040qGYf1YdvFi9Tqk6ek0SyapSbrD_DT_nSfOgk4LDUmf95zkzVsUbxndNKyrP95v7242nHK6eWSMGr5hFeXVs2LFadOuBSvF82JFuajXnWiql8WrGB8ozkVXr4rfdypBcMoS5QbiwDuVcOKXpP0BIhm9tf5o3J6kCYhxKfhh0cl4R_xIfEB2Os1-b09awcFoovbgUtYFsoeYVEYRGozqIWHBA1hr0hLJEQIQbDKroHoLJHksHxdrHDl457FdUPMJ10g6ejKZmHwwGktpP_mQ4uvixahshDdP41Xx8_P1j93X9e33L99229u1FrxL6w7qBpSoSzaUQrWdrisOirdV01clpwNrAeq20eVQ9QIq1kPT1XVXduXIKWt5eVVsznWjNmC9fPBL9ivK--ypzJ5m8_HJH9ah4MNZMAf_a0EP5MFEjcdWaO8SJa94KUpB2xbRd2d0ryxI40afgtIZl9ua4fbKqq3-7eCCwnfIjnsHo8H1C8H7_wQTKJum6O2S7yJegvUZ1MHHGGCUczAHFU6SUZnDJXO4ZD6fPIdL_g0XCj89maJ64yDJqGBeejmlNEc5DVZOmCdsnv8xKlB_fbOTrNfdMLQa7-IPHJjafQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2423535088</pqid></control><display><type>article</type><title>Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts</title><source>Sabinet Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>African Journals Online (Open Access)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Norris, S.A. ; Huddle, K.R. ; Klipstein-Grobusch, K. ; Soepnel, L. ; Levitt, N. ; Nicolaou, V.</creator><creatorcontrib>Norris, S.A. ; Huddle, K.R. ; Klipstein-Grobusch, K. ; Soepnel, L. ; Levitt, N. ; Nicolaou, V.</creatorcontrib><description>Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) increasingly being viewed as potential alternatives.Objectives. To compare maternal and neonatal outcomes in two cohorts of women with GDM exposed to either insulin monotherapy or OHAs.Methods. A retrospective medical record review at Chris Hani Baragwanath Academic Hospital in South Africa was conducted for women with GDM diagnosed using the 100 g oral glucose tolerance test and/or random capillary blood glucose &gt;11.1 mmol/L in 2010 - 2014. The findings were compared with a previous audit at the same clinic for the period 1992 - 2002. Variables of interest included maternal demographics, maternal comorbidities, glycaemic indices, treatments used during pregnancy, and obstetric and neonatal outcomes.Results. A total of 192 women with GDM were identified for 2010 - 2014, and there were 348 women in the previous audit (1992 - 2002). Baseline characteristics and outcomes of women in the two cohorts were similar apart from earlier presentation (mean (standard deviation) gestational age (GA) 27 (7.5) weeks v. 28.3 (6.4) weeks; p=0.04), lower GA at delivery (36.3 (3.6) weeks v. 37 (1.6) weeks); p=0.008) and lower macrosomia rates (12.5% v. 4.9%; p=0.011) in the later cohort. When comparing the individual OHAs against insulin in the later cohort, both agents were comparable to insulin in terms of maternal and neonatal outcomes.Conclusions. This study contributes to the paucity of data on the safety of OHAs in GDM pregnancy in terms of maternal and neonatal outcomes. OHAs were shown to be an effective alternative to insulin for women with GDM in whom lifestyle measures fail, particularly in a resource-poor setting.</description><identifier>ISSN: 0256-9574</identifier><identifier>ISSN: 2078-5135</identifier><identifier>EISSN: 2078-5135</identifier><identifier>DOI: 10.7196/SAMJ.2020.v110i2.14024</identifier><language>eng</language><publisher>South African Medical Association NPC</publisher><subject>Blood glucose ; Child health ; Comorbidity ; Diabetes mellitus ; Diabetes therapy ; Drug therapy ; Gestational diabetes ; Glucose ; Glucose intolerance ; Glucose tolerance test ; Health Care Sciences &amp; Services ; Health Policy &amp; Services ; Hypoglycemic agents ; Insulin ; Medical Ethics ; Medical records ; Medicine, General &amp; Internal ; Medicine, Legal ; Medicine, Research &amp; Experimental ; Newborn infants ; Obstetrics ; Pregnancy ; Setting (Literature) ; Type 2 diabetes ; Women</subject><ispartof>SAMJ: South African Medical Journal, 2020-02, Vol.110 (2), p.154-158</ispartof><rights>COPYRIGHT 2020 Health &amp; Medical Publishing Group</rights><rights>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-9e67ea5631d35a89c642ea2847b4320d18ee687c3d4b5e41be79669393f201823</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,864,885,27924,27925,39242</link.rule.ids></links><search><creatorcontrib>Norris, S.A.</creatorcontrib><creatorcontrib>Huddle, K.R.</creatorcontrib><creatorcontrib>Klipstein-Grobusch, K.</creatorcontrib><creatorcontrib>Soepnel, L.</creatorcontrib><creatorcontrib>Levitt, N.</creatorcontrib><creatorcontrib>Nicolaou, V.</creatorcontrib><title>Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts</title><title>SAMJ: South African Medical Journal</title><addtitle>SAMJ, S. Afr. med. j</addtitle><description>Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) increasingly being viewed as potential alternatives.Objectives. To compare maternal and neonatal outcomes in two cohorts of women with GDM exposed to either insulin monotherapy or OHAs.Methods. A retrospective medical record review at Chris Hani Baragwanath Academic Hospital in South Africa was conducted for women with GDM diagnosed using the 100 g oral glucose tolerance test and/or random capillary blood glucose &gt;11.1 mmol/L in 2010 - 2014. The findings were compared with a previous audit at the same clinic for the period 1992 - 2002. Variables of interest included maternal demographics, maternal comorbidities, glycaemic indices, treatments used during pregnancy, and obstetric and neonatal outcomes.Results. A total of 192 women with GDM were identified for 2010 - 2014, and there were 348 women in the previous audit (1992 - 2002). Baseline characteristics and outcomes of women in the two cohorts were similar apart from earlier presentation (mean (standard deviation) gestational age (GA) 27 (7.5) weeks v. 28.3 (6.4) weeks; p=0.04), lower GA at delivery (36.3 (3.6) weeks v. 37 (1.6) weeks); p=0.008) and lower macrosomia rates (12.5% v. 4.9%; p=0.011) in the later cohort. When comparing the individual OHAs against insulin in the later cohort, both agents were comparable to insulin in terms of maternal and neonatal outcomes.Conclusions. This study contributes to the paucity of data on the safety of OHAs in GDM pregnancy in terms of maternal and neonatal outcomes. OHAs were shown to be an effective alternative to insulin for women with GDM in whom lifestyle measures fail, particularly in a resource-poor setting.</description><subject>Blood glucose</subject><subject>Child health</subject><subject>Comorbidity</subject><subject>Diabetes mellitus</subject><subject>Diabetes therapy</subject><subject>Drug therapy</subject><subject>Gestational diabetes</subject><subject>Glucose</subject><subject>Glucose intolerance</subject><subject>Glucose tolerance test</subject><subject>Health Care Sciences &amp; Services</subject><subject>Health Policy &amp; Services</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Medical Ethics</subject><subject>Medical records</subject><subject>Medicine, General &amp; Internal</subject><subject>Medicine, Legal</subject><subject>Medicine, Research &amp; Experimental</subject><subject>Newborn infants</subject><subject>Obstetrics</subject><subject>Pregnancy</subject><subject>Setting (Literature)</subject><subject>Type 2 diabetes</subject><subject>Women</subject><issn>0256-9574</issn><issn>2078-5135</issn><issn>2078-5135</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>JRA</sourceid><recordid>eNpVkl2L1DAUhosoOK7-BQkI4s2MSdr040qGYf1YdvFi9Tqk6ek0SyapSbrD_DT_nSfOgk4LDUmf95zkzVsUbxndNKyrP95v7242nHK6eWSMGr5hFeXVs2LFadOuBSvF82JFuajXnWiql8WrGB8ozkVXr4rfdypBcMoS5QbiwDuVcOKXpP0BIhm9tf5o3J6kCYhxKfhh0cl4R_xIfEB2Os1-b09awcFoovbgUtYFsoeYVEYRGozqIWHBA1hr0hLJEQIQbDKroHoLJHksHxdrHDl457FdUPMJ10g6ejKZmHwwGktpP_mQ4uvixahshDdP41Xx8_P1j93X9e33L99229u1FrxL6w7qBpSoSzaUQrWdrisOirdV01clpwNrAeq20eVQ9QIq1kPT1XVXduXIKWt5eVVsznWjNmC9fPBL9ivK--ypzJ5m8_HJH9ah4MNZMAf_a0EP5MFEjcdWaO8SJa94KUpB2xbRd2d0ryxI40afgtIZl9ua4fbKqq3-7eCCwnfIjnsHo8H1C8H7_wQTKJum6O2S7yJegvUZ1MHHGGCUczAHFU6SUZnDJXO4ZD6fPIdL_g0XCj89maJ64yDJqGBeejmlNEc5DVZOmCdsnv8xKlB_fbOTrNfdMLQa7-IPHJjafQ</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Norris, S.A.</creator><creator>Huddle, K.R.</creator><creator>Klipstein-Grobusch, K.</creator><creator>Soepnel, L.</creator><creator>Levitt, N.</creator><creator>Nicolaou, V.</creator><general>South African Medical Association NPC</general><general>Health &amp; Medical Publishing Group</general><general>Health and Medical Publishing Group</general><scope>AEIZH</scope><scope>JRA</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope></search><sort><creationdate>20200201</creationdate><title>Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts</title><author>Norris, S.A. ; Huddle, K.R. ; Klipstein-Grobusch, K. ; Soepnel, L. ; Levitt, N. ; Nicolaou, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-9e67ea5631d35a89c642ea2847b4320d18ee687c3d4b5e41be79669393f201823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood glucose</topic><topic>Child health</topic><topic>Comorbidity</topic><topic>Diabetes mellitus</topic><topic>Diabetes therapy</topic><topic>Drug therapy</topic><topic>Gestational diabetes</topic><topic>Glucose</topic><topic>Glucose intolerance</topic><topic>Glucose tolerance test</topic><topic>Health Care Sciences &amp; Services</topic><topic>Health Policy &amp; Services</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Medical Ethics</topic><topic>Medical records</topic><topic>Medicine, General &amp; Internal</topic><topic>Medicine, Legal</topic><topic>Medicine, Research &amp; Experimental</topic><topic>Newborn infants</topic><topic>Obstetrics</topic><topic>Pregnancy</topic><topic>Setting (Literature)</topic><topic>Type 2 diabetes</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Norris, S.A.</creatorcontrib><creatorcontrib>Huddle, K.R.</creatorcontrib><creatorcontrib>Klipstein-Grobusch, K.</creatorcontrib><creatorcontrib>Soepnel, L.</creatorcontrib><creatorcontrib>Levitt, N.</creatorcontrib><creatorcontrib>Nicolaou, V.</creatorcontrib><collection>Sabinet:Open Access</collection><collection>Sabinet Open Access Journals</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><jtitle>SAMJ: South African Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Norris, S.A.</au><au>Huddle, K.R.</au><au>Klipstein-Grobusch, K.</au><au>Soepnel, L.</au><au>Levitt, N.</au><au>Nicolaou, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts</atitle><jtitle>SAMJ: South African Medical Journal</jtitle><addtitle>SAMJ, S. Afr. med. j</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>110</volume><issue>2</issue><spage>154</spage><epage>158</epage><pages>154-158</pages><issn>0256-9574</issn><issn>2078-5135</issn><eissn>2078-5135</eissn><abstract>Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) increasingly being viewed as potential alternatives.Objectives. To compare maternal and neonatal outcomes in two cohorts of women with GDM exposed to either insulin monotherapy or OHAs.Methods. A retrospective medical record review at Chris Hani Baragwanath Academic Hospital in South Africa was conducted for women with GDM diagnosed using the 100 g oral glucose tolerance test and/or random capillary blood glucose &gt;11.1 mmol/L in 2010 - 2014. The findings were compared with a previous audit at the same clinic for the period 1992 - 2002. Variables of interest included maternal demographics, maternal comorbidities, glycaemic indices, treatments used during pregnancy, and obstetric and neonatal outcomes.Results. A total of 192 women with GDM were identified for 2010 - 2014, and there were 348 women in the previous audit (1992 - 2002). Baseline characteristics and outcomes of women in the two cohorts were similar apart from earlier presentation (mean (standard deviation) gestational age (GA) 27 (7.5) weeks v. 28.3 (6.4) weeks; p=0.04), lower GA at delivery (36.3 (3.6) weeks v. 37 (1.6) weeks); p=0.008) and lower macrosomia rates (12.5% v. 4.9%; p=0.011) in the later cohort. When comparing the individual OHAs against insulin in the later cohort, both agents were comparable to insulin in terms of maternal and neonatal outcomes.Conclusions. This study contributes to the paucity of data on the safety of OHAs in GDM pregnancy in terms of maternal and neonatal outcomes. OHAs were shown to be an effective alternative to insulin for women with GDM in whom lifestyle measures fail, particularly in a resource-poor setting.</abstract><pub>South African Medical Association NPC</pub><doi>10.7196/SAMJ.2020.v110i2.14024</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0256-9574
ispartof SAMJ: South African Medical Journal, 2020-02, Vol.110 (2), p.154-158
issn 0256-9574
2078-5135
2078-5135
language eng
recordid cdi_scielo_journals_S0256_95742020000200019
source Sabinet Open Access Journals; DOAJ Directory of Open Access Journals; African Journals Online (Open Access); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Blood glucose
Child health
Comorbidity
Diabetes mellitus
Diabetes therapy
Drug therapy
Gestational diabetes
Glucose
Glucose intolerance
Glucose tolerance test
Health Care Sciences & Services
Health Policy & Services
Hypoglycemic agents
Insulin
Medical Ethics
Medical records
Medicine, General & Internal
Medicine, Legal
Medicine, Research & Experimental
Newborn infants
Obstetrics
Pregnancy
Setting (Literature)
Type 2 diabetes
Women
title Maternal and neonatal outcomes following the introduction of oral hypoglycaemic agents for gestational diabetes mellitus were comparable to insulin monotherapy in two historical cohorts
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A54%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maternal%20and%20neonatal%20outcomes%20following%20the%20introduction%20of%20oral%20hypoglycaemic%20agents%20for%20gestational%20diabetes%20mellitus%20were%20comparable%20to%20insulin%20monotherapy%20in%20two%20historical%20cohorts&rft.jtitle=SAMJ:%20South%20African%20Medical%20Journal&rft.au=Norris,%20S.A.&rft.date=2020-02-01&rft.volume=110&rft.issue=2&rft.spage=154&rft.epage=158&rft.pages=154-158&rft.issn=0256-9574&rft.eissn=2078-5135&rft_id=info:doi/10.7196/SAMJ.2020.v110i2.14024&rft_dat=%3Cgale_sciel%3EA613203484%3C/gale_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2423535088&rft_id=info:pmid/&rft_galeid=A613203484&rft_sabinet_id=https://hdl.handle.net/10520/EJC-1bc9dd8c1d&rft_scielo_id=S0256_95742020000200019&rfr_iscdi=true